Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Florquinitau F 18→

Florquinitau F 18 Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Tau-targeted fluorine-18 radiopharmaceuticaldiagnostic PET imaging agent
Mechanism of action
Binds to aggregated tau protein in the brain, including tau neurofibrillary tangles. After intravenous administration it crosses the blood-brain barrier and accumulates in regions containing tau aggregates; fluorine-18 positron emissions permit PET visualisation.
Indications / reported uses
  • PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary-tangle pathology, under the US TAUKLARIFY product indication.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220496Orig1s000lbl.pdf · https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220496Orig1s000MultidisciplineR.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Florquinitau F 18 Environmental Risk Assessment (ERA) (the Florquinitau F 18 ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.